However, IgG anti-CCP2-, IgM RF- RA patients with anti-Carb at baseline had lower disease activity by DAS28 than anti-Carb negative in 48-month follow up after disease onset and standard of care DMARD treatment (52). This evidence concerns the gene AGBL2 and rheumatoid arthritis.